Drug Trial Radar · NCT05750797
The Nationwide Real-world Status of Oral Corticosteroid Use in Patients With Asthma
Last checked: Nov 20, 2026Latest source record: Mar 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
800,000
Planned (sponsor's estimate)
Start
Mar 1, 2023
Primary completion
Dec 2023
Study completion Dec 2023
Sponsor
- Lead sponsor
- Joon Young ChoiAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Seoul St. Mary's Hospital; Hallym University Medical Center; Konkuk University Hospital
- First posted
- Mar 2, 2023
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 15 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Health Insurance Review and Assessment Service (HIRA) database contains nationwide claim data. By utilizing this database, the investigators aimed to analyze the current status of OCS use in South Korea by using HIRA database.
Conditions
- Asthma
- Corticosteroid
Interventions
Oral corticosteroidsDrug
The prescription of OCS will be analyzed. OCS included betamethasone, deflazacort, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, and triamcinolone.
Primary outcomes
What the sponsor says the trial is designed to measure.
- OCS prescription ratesTime frame: 1-year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Incheon St. Mary's Hospital
Incheon, Gyeongki, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.